Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) was the recipient of a large growth in short interest during the month of November. As of November 30th, there was short interest totalling 28,100 shares, a growth of 5.2% from the November 15th total of 26,700 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days.
Basilea Pharmaceutica Price Performance
Shares of BPMUF opened at $52.83 on Wednesday. The stock has a 50 day moving average of $52.74 and a 200 day moving average of $50.37. Basilea Pharmaceutica has a 12 month low of $38.60 and a 12 month high of $52.83.
Analysts Set New Price Targets
Separately, HC Wainwright upgraded shares of Basilea Pharmaceutica to a “strong-buy” rating in a report on Monday, September 23rd.
About Basilea Pharmaceutica
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
Featured Stories
- Five stocks we like better than Basilea Pharmaceutica
- Best Stocks Under $10.00
- AppLovin Insiders Sell Shares: Stock Price Indicated Higher
- Learn Technical Analysis Skills to Master the Stock Market
- Broadcom’s Stellar Outlook Sparks Hopes for a Semi Sector Rally
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Salesforce’s Clear Path to $400 and Beyond
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
